<DOC>
	<DOCNO>NCT01986166</DOCNO>
	<brief_summary>This open-label , multicenter , global Phase Ib study evaluate safety , tolerability pharmacokinetics intravenous ( IV ) dose MEHD7945A combination oral dose cobimetinib patient locally advance metastatic solid tumor carry Kirsten Rat Sarcoma Viral Oncogene Homolog ( KRAS ) mutation standard therapy exist , proven ineffective intolerable consider inappropriate . The study comprise dose-escalation ( Stage 1 ) indication-specific cohort expansion stage ( Stage 2 ) .</brief_summary>
	<brief_title>A Study MEHD7945A Cobimetinib Patients With Locally Advanced Metastatic Cancers With Mutant KRAS</brief_title>
	<detailed_description />
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>Locally advanced metastatic solid KRASmutant tumor , standard therapy exist , proven ineffective intolerable consider inappropriate Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Evaluable disease disease measurable per modify Response Evaluation Criteria Solid Tumors version 1.1 ( RECIST v1.1 ) Consent provide archival tumor tissue biomarker test Additionally , patient consider enrollment indication specific expansion cohort Stage 2 , current cancer must either KRASmutant colorectal cancer ( CRC ) KRASmutant nonsmall cell lung cancer ( NSCLC ) History prior significant toxicity another MEK pathway inhibitor combination another MEK epidermal growth factor receptor ( EGFR ) inhibitor require discontinuation treatment Previous treatment combination MEK inhibitor EGFR inhibitor ( applies indication specific expansion cohort Stage 2 ) Allergy hypersensitivity component cobimetinib formulation History severe ( Grade 3 4 ) allergic hypersensitivity reaction therapeutic antibody require discontinuation therapy History interstitial lung disease ( ILD ) Known severe ulcer disease History evidence retinal pathology ophthalmologic examination consider risk factor neurosensory retinal detachment , central serous chorioetinopathy ( CSCR ) , retinal vein occlusion ( RVO ) , neovascular macular degeneration Patients exclude currently either follow condition identify risk factor CSCR : Uncontrolled glaucoma intraocular pressure great ( &gt; ) 21 millimeter mercury ( mm Hg ) Grade great equal ( &gt; = ) 3 hypertriglyceridemia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>